Although mutations in BTK and/or PLCG2 have been established as the dominant mechanism of ibrutinib resistance in CLL, in many patients such mutations are present in only a minor subclone at the time of progression, suggesting that additional genetic lesions may contribute to ibrutinib resistance [49–52]. This evidence concerns the gene PLCG2 and B-cell chronic lymphocytic leukemia.